Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
NLS Pharmaceutics ( (NLSP) ) has issued an update.
On January 28, 2025, NLS Pharmaceutics announced the launch of a preclinical program to evaluate Mazindol ER as a treatment for fentanyl dependence, a major health crisis. This initiative addresses the need for non-opioid treatment alternatives and capitalizes on Mazindol’s unique pharmacological profile, which targets multiple neurotransmitter systems. The program represents a significant step towards potentially transformative therapy, with implications for advancing clinical development and commercialization opportunities. NLS’s patent-protected Mazindol ER, with coverage until beyond 2038, strengthens the company’s market positioning in opioid addiction treatment.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company focused on developing therapies for rare and complex central nervous system disorders. Founded in 2015 and headquartered in Switzerland, the company collaborates with global partners and renowned scientists to address unmet medical needs. NLS is engaged in developing a range of innovative treatment candidates, including its Dual Orexin Agonist platform.
YTD Price Performance: -16.97%
Average Trading Volume: 1,087,038
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.4M
See more data about NLSP stock on TipRanks’ Stock Analysis page.
